MA28179A1 - NEW COMPOUND, COMPOSITIONS THEREFOR, METHODS OF MAKING AND / OR PROCESSING - Google Patents

NEW COMPOUND, COMPOSITIONS THEREFOR, METHODS OF MAKING AND / OR PROCESSING

Info

Publication number
MA28179A1
MA28179A1 MA29057A MA29057A MA28179A1 MA 28179 A1 MA28179 A1 MA 28179A1 MA 29057 A MA29057 A MA 29057A MA 29057 A MA29057 A MA 29057A MA 28179 A1 MA28179 A1 MA 28179A1
Authority
MA
Morocco
Prior art keywords
methods
making
processing
new compound
preparation
Prior art date
Application number
MA29057A
Other languages
French (fr)
Inventor
Orco Philip C Dell
Ann Marie Diederich
Qiaogang Su
Jeffrey Lee Wood
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA28179A1 publication Critical patent/MA28179A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Composé nouveau, compositions correspondantes, procédés de préparation et/ou méthodes de traitement II est présenté une forme cristalline nouvelle de pentahydrate de monochlorhydrate de topotécan qui est un pentahydrate de monochrlohydrate de 10[(diméthyl-amino)méthyl] -4-éthyl-4, 9-dihydroxy- lH-pyrano [31 , 4 ' :6,7] -indolizino[1,2-b]quinoléine-3,14(4H, 12H)dione, des compo¬sitions pharmaceutiques correspondantes, des procédés pour leur préparation et/ou des méthodes pour leur utilisation à des fins de traitement de maladies virales et/ou en rapport avec le cancer.Novel compound, corresponding compositions, methods of preparation and / or methods of treatment A novel crystalline form of topotecan monohydrochloride pentahydrate which is a [4- (dimethylamino) methyl] -4-ethyl-4-monochlorohydrate pentahydrate is presented. , 9-dihydroxy-1H-pyrano [31,4 ': 6,7] -indolizino [1,2-b] quinoline-3,14 (4H, 12H) dione, corresponding pharmaceutical compositions, processes for their preparation, preparation and / or methods for their use for the treatment of viral diseases and / or in connection with cancer.

MA29057A 2003-11-12 2006-05-24 NEW COMPOUND, COMPOSITIONS THEREFOR, METHODS OF MAKING AND / OR PROCESSING MA28179A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51916003P 2003-11-12 2003-11-12
US52457403P 2003-11-24 2003-11-24

Publications (1)

Publication Number Publication Date
MA28179A1 true MA28179A1 (en) 2006-09-01

Family

ID=34594951

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29057A MA28179A1 (en) 2003-11-12 2006-05-24 NEW COMPOUND, COMPOSITIONS THEREFOR, METHODS OF MAKING AND / OR PROCESSING

Country Status (16)

Country Link
US (2) US7754733B2 (en)
EP (1) EP1689400A4 (en)
JP (1) JP2007510751A (en)
KR (1) KR20060122847A (en)
CN (1) CN1913897B (en)
AR (1) AR046579A1 (en)
AU (1) AU2004289318B2 (en)
BR (1) BRPI0416366A (en)
CA (1) CA2545876A1 (en)
IL (1) IL175369A (en)
IS (1) IS8491A (en)
MA (1) MA28179A1 (en)
NO (1) NO20062616L (en)
RU (1) RU2352572C2 (en)
TW (1) TWI333492B (en)
WO (1) WO2005046608A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046579A1 (en) * 2003-11-12 2005-12-14 Smithkline Beecham Corp TOPOTECAN CRYSTAL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE IT AND ITS USE TO PREPARE SUCH PHARMACEUTICAL COMPOSITION
EP1943253A1 (en) * 2005-10-10 2008-07-16 Cipla Limited Novel crystalline forms
US7547785B2 (en) * 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
US7977483B2 (en) 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
KR20100016419A (en) 2007-04-19 2010-02-12 시노팜 타이완 리미티드 Crystalline forms of topotecan hydrochloride and processes for making the same
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
ITMI20072268A1 (en) 2007-12-04 2009-06-05 Antibioticos Spa CRYSTALLINE POLYMORPHOS OF TOPOTECAN CHLORIDRATE WITH HIGH DEGREE OF PURITY AND METHODS FOR THEIR PREPARATION
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
WO1992005785A1 (en) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Water soluble camptothecin analogues, processes and methods
AR013261A1 (en) * 1997-08-01 2000-12-13 Smithkline Beecham Corp PHARMACEUTICAL FORMULATIONS FOR CAMPTOTECINE ANALOGS IN A GELATIN CAPSULE
CA2461089A1 (en) * 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of 20(s)-camptothecins
US7049322B2 (en) * 2002-02-21 2006-05-23 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
AR046579A1 (en) * 2003-11-12 2005-12-14 Smithkline Beecham Corp TOPOTECAN CRYSTAL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE IT AND ITS USE TO PREPARE SUCH PHARMACEUTICAL COMPOSITION
EP1943253A1 (en) 2005-10-10 2008-07-16 Cipla Limited Novel crystalline forms
US7547785B2 (en) * 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
KR20100016419A (en) * 2007-04-19 2010-02-12 시노팜 타이완 리미티드 Crystalline forms of topotecan hydrochloride and processes for making the same
ITMI20072268A1 (en) * 2007-12-04 2009-06-05 Antibioticos Spa CRYSTALLINE POLYMORPHOS OF TOPOTECAN CHLORIDRATE WITH HIGH DEGREE OF PURITY AND METHODS FOR THEIR PREPARATION

Also Published As

Publication number Publication date
TWI333492B (en) 2010-11-21
US20100210677A1 (en) 2010-08-19
WO2005046608A3 (en) 2005-11-03
AR046579A1 (en) 2005-12-14
WO2005046608A2 (en) 2005-05-26
IS8491A (en) 2006-05-30
US20070117832A1 (en) 2007-05-24
US8158645B2 (en) 2012-04-17
JP2007510751A (en) 2007-04-26
NO20062616L (en) 2006-07-12
US7754733B2 (en) 2010-07-13
KR20060122847A (en) 2006-11-30
CN1913897B (en) 2010-08-11
BRPI0416366A (en) 2007-03-13
RU2006120422A (en) 2007-12-27
IL175369A0 (en) 2008-04-13
EP1689400A4 (en) 2006-12-27
CA2545876A1 (en) 2005-05-26
AU2004289318A1 (en) 2005-05-26
AU2004289318B2 (en) 2010-04-29
EP1689400A2 (en) 2006-08-16
RU2352572C2 (en) 2009-04-20
IL175369A (en) 2012-03-29
WO2005046608B1 (en) 2005-12-29
TW200530250A (en) 2005-09-16
CN1913897A (en) 2007-02-14

Similar Documents

Publication Publication Date Title
MA28179A1 (en) NEW COMPOUND, COMPOSITIONS THEREFOR, METHODS OF MAKING AND / OR PROCESSING
CN1318031C (en) Compositions contg. benzoxazinone and nucleoside like materials
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
CA2442557A1 (en) Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
MA30000B1 (en) NOVEL CRYSTALLINE FORM OF A PYRIDAZINO [4,5-B] INDOLE DERIVATIVE
WO2006029146A3 (en) 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
HUP0303128A2 (en) Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it
IL164974A0 (en) Novel compounds and their use
NO20000313D0 (en) New connections
JP2002520273A5 (en)
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
PT1730144E (en) Substituted 1,4,8-triazaspiro¬4.5 decan-2-one compounds
JP2007516193A5 (en)
GT200200081A (en) SALT CITRATE OF 5,8,14-TRIAZATETRACICLO [10.3.1.0 2,11.0 4,9] HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
WO2003045324A3 (en) 14-methyl-epothilones
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
TW200517127A (en) Novel composition
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2003045940A3 (en) Benzazepine derivatives and their use as 5-ht ligands
ATE297926T1 (en) HEXAHYDROPYRAZINO(1'2':1,6)-PYRIDO(3,4-B)INDOLE 1,4-DIONE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND ERECTION DISORDERS
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists